DIC
TCRX icon

Deer IX & Co’s TScan Therapeutics TCRX Stock Holding History

Deer IX & Co’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$9.35M Buy
+1,245,505
New +$11.6M 0.96% 6

Other funds holding TCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deer IX & Co's TCRX Position: Q3 2021 in Review

Deer IX & Co opened a new position in TScan Therapeutics (TCRX) in Q3 2021: 1,245,505 shares worth $9.35M. The stake represents 0.96% of the portfolio and ranks #6 among its holdings.

27 funds tracked by Wall St. Rank hold TCRX as of Q3 2021.

  • Deer IX & Co held 1,245,505 shares of TScan Therapeutics worth $9.35M as of Q3 2021.
  • TScan Therapeutics was a new Deer IX & Co position in Q3 2021.
  • TScan Therapeutics made up 0.96% of Deer IX & Co's portfolio in Q3 2021, its #6 holding.
  • 27 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2021.

Based on Deer IX & Co's 13F filing for Q3 2021, filed 15 Nov 2021.